HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

177Lu-3PRGD2

an antineoplastic agent that targets integrin alphavbeta3; structure in first source

Also Known As:

177Lu-3PRGD(2)

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - 177Lu-3PRGD2: 1
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - 177Lu-3PRGD2: 1
Inorganic Chemicals: 9
- Coordination Complexes: 576
  - 177Lu-3PRGD2: 1
Organic Chemicals: 133
- Coordination Complexes: 576
  - 177Lu-3PRGD2: 1

Related Diseases

1.

Neoplasms (Cancer)

06/23/2022 - "[177Lu]Lu-DOTA-Palm-3PRGD2 (177Lu-Palm-3PRGD2) retained a specific binding affinity for integrin αvβ3/αvβ5, with an IC50 value of 5.13 ± 1.16 nM. Compared with 177Lu-3PRGD2, the 177Lu-Palm-3PRGD2 circulation time in blood was more than 6 times longer (slow half-life: 73.42 min versus 11.81 min), and the tumor uptake increased more than fivefold (21.34 ± 4.65 %IA/g and 4.11 ± 0.70 %IA/g at 12 h post-injection). "

Related Drugs and Biologics

1.	Integrins
2.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid